4519 中外薬

累計 / 通期：4Q / 3Q / 2Q / 1Q

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2024/12	4Q	1,170,611	542,002	46.3%	-	-	387,317	33.1%	235.39	5.3%	23.4%	0.0%	19.0%
2023/12	4Q	1,111,367	439,174	39.5%	-	-	325,472	29.3%	197.83	-11.8%	-17.7%	0.0%	-13.1%
2022/12	4Q	1,259,946	533,309	42.3%	-	-	374,429	29.7%	227.64	26.0%	26.4%	0.0%	23.6%
2021/12	4Q	999,759	421,897	42.2%	-	-	302,995	30.3%	184.29	27.0%	40.1%	0.0%	41.1%
2020/12	4Q	786,946	301,230	38.3%	-	-	214,733	27.3%	130.66	14.7%	43.0%	0.0%	36.3%
2019/12	4Q	686,184	210,597	30.7%	-	-	157,560	23.0%	287.84	18.4%	69.4%	0.0%	70.4%
2018/12	4Q	579,787	124,323	21.4%	-	-	92,488	16.0%	169.08	-	-	-	-

決算期	四半期	売上高	営業利益	営業利益率	経常利益	経常利益率	純利益	純利益率	EPS	売上高前年比	営業利益前年比	経常利益前年比	純利益前年比
2024/12	4Q	1,170,611	542,002	46.3%	-	-	387,317	33.1%	235.39	5.3%	23.4%	0.0%	19.0%
2023/12	4Q	1,111,367	439,174	39.5%	-	-	325,472	29.3%	197.83	-11.8%	-17.7%	0.0%	-13.1%
2022/12	4Q	1,259,946	533,309	42.3%	-	-	374,429	29.7%	227.64	26.0%	26.4%	0.0%	23.6%
2021/12	4Q	999,759	421,897	42.2%	-	-	302,995	30.3%	184.29	27.0%	40.1%	0.0%	41.1%
2020/12	4Q	786,946	301,230	38.3%	-	-	214,733	27.3%	130.66	14.7%	43.0%	0.0%	36.3%
2019/12	4Q	686,184	210,597	30.7%	-	-	157,560	23.0%	287.84	18.4%	69.4%	0.0%	70.4%
2018/12	4Q	579,787	124,323	21.4%	-	-	92,488	16.0%	169.08	-	-	-	-